ArticleImmunity, inflammation and disease2026
MAFG Induces the Methylation of CRYAB to Promote the Activation of A1 Astrocyte After Spinal Cord Injury.
Article in Immunity, inflammation and disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- MAFG Induces the Methylation of CRYAB to Promote the Activation of A1 Astrocyte After Spinal Cord Injury.Immunity, inflammation and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
purposeTo investigate the effects of MAF bZIP transcription factor G (MAFG) on the transformation of A1/A2 reactive astrocytes and the production of inflammatory factors after spinal cord injury (SCI).
methodsAn SCI model was established using Sprague-Dawley rats. Astrocyte conditioned medium (ACM) and lipopolysaccharide (LPS) were used to induce the generation of type A1 astrocytes. MAFG-, CRYAB-, C3-, and S100A10-positive cells were examined using immunofluorescence. The expression of MAFG, TNF-α, IL-1β, IL-6, C3, Serping1, Sphk1, S100A10, CRYAB, DNMT1, DNMT3a, and DNMT3b was detected through RT-PCR and/or Western blot. The inclined plate test and Basso-Beattie-Bresnahan scores were used to evaluate the motor function in rats. Hematoxylin and eosin and Nissl staining were performed to assess pathological changes in the rat spinal tissues. In rat astrocytes, IL-1β and IL-6 levels were examined via enzyme-linked immunosorbent assay.
resultsA1 astrocyte activation was accompanied by MAFG upregulation in rat spinal cord tissues after SCI. MAFG silencing inhibited the activation of A1 astrocytes and inflammation and improved neurological outcomes and functional recovery in rats after SCI. In ACM-treated rat astrocytes, MAFG silencing inhibited A1 astrocyte activation, inflammation, and CRYAB methylation. Moreover, 5-Aza (an inhibitor of methylation) further inhibited the activation of A1 astrocytes and inflammation, whereas DNMT3b overexpression had the opposite effect.
conclusionSilencing MAFG reduced the activation of A1 astrocytes and neuroinflammation and improved functional recovery after SCI, which might be involved in the inhibition of CRYAB methylation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.